Literature DB >> 6097166

Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults.

A M Brisson, A Bryskier, L Millerioux, J B Fourtillan.   

Abstract

We studied the pharmacokinetics of cefotiam, a parenteral cephalosporin, at intravenous doses of 0.5, 1, and 2 g and intramuscular doses of 0.5 and 1 g in two groups of eight healthy adult volunteers. The concentrations of cefotiam in plasma were determined over a period of 5 or 6 h and in urine over 24 h, using high-pressure liquid chromatographic procedures. Plasma concentration-time data were fitted to a three-exponential equation for the intravenous administration, and after intramuscular administration, the data were analyzed by a two-compartment or a one-compartment open model. Over the above dosing range and routes of administration, cefotiam pharmacokinetics were essentially linear, with plasma clearances varying from 19.6 to 22.5 liters/h. No significant differences were observed with respect to the terminal half-life (1 h) and the area under the curve versus the dose. Intramuscularly injected cefotiam was 63 to 74% available. The fraction of dose excreted unchanged in urine (0.50 to 0.67) indicated a substantial nonrenal mechanism of elimination. The apparent volume of distribution (about 30 liters) was higher than those of other parenteral cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097166      PMCID: PMC179955          DOI: 10.1128/AAC.26.4.513

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  IGPHARM: interactive graphic package for pharmacokinetic analysis.

Authors:  C Gomeni; R Gomeni
Journal:  Comput Biomed Res       Date:  1978-08

2.  Comparative pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.

Authors:  T Bergan
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

3.  Cefotiam concentrations in bile and in the wall of the gallbladder in patients with biliary disease.

Authors:  K Satake; K Cho; M Taniura; I Oka; I Koo
Journal:  J Antimicrob Chemother       Date:  1982-08       Impact factor: 5.790

4.  Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents.

Authors:  I H Patel; R E Weinfeld; J Konikoff; M Parsonnet
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  Pharmacokinetic study of cefadroxil following single and repeated doses.

Authors:  A M Brisson; J B Fourtillan
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

6.  Cefamandole: in vitro and clinical pharmacokinetics.

Authors:  R S Griffith; H R Black; G L Brier; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

7.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

8.  Comparative in vitro study in new cephalosporins.

Authors:  G P Bodey; V Fainstein; A M Hinkle
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

9.  [Comparative pharmacokinetics of moxalactam and other cephalosporins].

Authors:  J B Fourtillan; A M Brisson
Journal:  Sem Hop       Date:  1983-06-30

10.  SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kida; M Kondo; H Ono; M Takeuchi; T Nishi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

View more
  7 in total

1.  Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers.

Authors:  L Maass; V Malerczyk; M Verho
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

2.  Pharmacokinetics of cefmetazole administered intramuscularly and intravenously to healthy adults.

Authors:  J Rodriguez-Barbero; E L Mariño; A Dominguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals.

Authors:  J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

4.  Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers.

Authors:  K Chiba; M Tsuchiya; J Kato; K Ochi; Z Kawa; T Ishizaki
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Skin tissue fluid levels of cefotiam in healthy man following oral cefotiam hexetil.

Authors:  H C Korting; M Schäfer-Korting; F Kees; A Lukacs; H Grobecker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

7.  Cefotiam susceptibility testing criteria.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.